ArticleCell2025
Generation of antigen-specific paired-chain antibodies using large language models.
Abstract read
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- AbAgKer: a unified semi-supervised framework for antigen-antibody binding affinity and kinetics prediction.Bioinformatics (Oxford, England) · 2026Article
- Language Model Embedding Classifiers Enable Identification of Multiple Sclerosis-Associated BCRs and Repertoires.bioRxiv : the preprint server for biology · 2026Article
- Mixture diffusion model for multimodal antibody design.Briefings in bioinformatics · 2026Article
- Evidence-aware comparison of sequence-centric machine learning for antibody discovery and optimization.Briefings in bioinformatics · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Predicting the evolutionary and functional landscapes of viruses with a unified nucleotide-protein language model: LucaVirus.National science review · 2026Article
- Generative AI-drivenAntibody therapeutics · 2026Article
- Norovirus-specific monoclonal antibodies that block histo-blood group antigen binding isolated from healthy donors.Journal of virology · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development.Microorganisms · 2026Review
- Exploiting plant immune "switches" for resistance engineering.Stress biology · 2026Review
- Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection.bioRxiv : the preprint server for biology · 2026Article
- Deep generative modeling captures maturation-dependent pairing patterns in human antibodies.iScience · 2026Article
- Article
- AI-driven discovery in protein science for immunology and infectious disease research.Frontiers in bioinformatics · 2026Review
- Highly Efficient Site-Specific and Cassette Mutagenesis of Plasmids Harboring GC-Rich Sequences.Cells · 2025Article
- De novo design of epitope-specific antibodies via a structure-driven computational workflow.Nature communications · 2025Article
- Targeting the roots of myeloid malignancies with T cell receptors.Nature reviews. Cancer · 2025Review
- Fine-tuned protein language model identifies antigen-specific B cell receptors from immune repertoires.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
24 authors.
Perry T WasdinProgram in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Center for Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Nicole V JohnsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Alexis K JankeVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sofia HeldDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Toma M MarinovCenter for Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Gwen JordaanVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Rebecca A GillespieVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Léna VandenabeeleDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Fani PantouliFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Olivia C PowersVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Matthew J VukovichVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Clinton M HoltProgram in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Center for Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jeongryeol KimDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Grant HansmanInstitute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, Gold Coast, QLD, Australia.
Jennifer LogueDivision of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA, USA.
Helen Y ChuDivision of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA, USA.
Sarah F AndrewsVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Masaru KanekiyoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Giuseppe A SauttoFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Ted M RossFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Daniel J ShewardDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Alexandra A Abu-ShmaisVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Ivelin S GeorgievProgram in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Center for Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Computer Science, Vanderbilt University, Nashville, TN, USA; Center for Structural Biology, Vanderbilt University, Nashville, TN, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37237, USA. Electronic address: ivelin.georgiev@vumc.org.
Funding
Influenza Vaccine Research and DevelopmentZIAAI005003 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2009 to 2025
$89.8MHigh-throughput mapping of antigen specificity to B-cell-receptor sequence for characterizing antibody responses in HIV-vaccinated and infected individualsR01AI152693 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2020 to 2023
$3.4MTechnologies for High-Throughput Mapping of Antigen Specificity to B-Cell-Receptor SequenceR01AI175245 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ivelin Georgiev · 2023 to 2026
$3.4MIntramural NIH HHS ZIA AI005003NIAID NIH HHS R01 AI152693NIAID NIH HHS R01 AI175245
Abstract
The traditional process of antibody discovery is limited by inefficiency, high costs, and low success rates. Recent approaches employing artificial intelligence (AI) have been developed to optimize existing antibodies and generate antibody sequences in a target-agnostic manner. In this work, we present MAGE (monoclonal antibody generator), a sequence-based protein language model (PLM) fine-tuned for the task of generating paired human variable heavy- and light-chain antibody sequences against targets of interest. We show that MAGE can generate novel and diverse antibody sequences with experimentally validated binding specificity against SARS-CoV-2, an emerging avian influenza H5N1, and respiratory syncytial virus A (RSV-A). MAGE represents a first-in-class model capable of designing human antibodies against multiple targets with no starting template.
Indexed as
Antibodies, MonoclonalAntibodies, ViralArtificial IntelligenceCOVID-19HumansImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsInfluenza A Virus, H5N1 SubtypeLarge Language ModelsSARS-CoV-2Antibodies, MonoclonalAntibodies, ViralImmunoglobulin Heavy ChainsImmunoglobulin Light Chainsantibody designartificial intelligencebiologicslanguage modelingmachine learningmonoclonal antibodyviruses
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.